CompanyNERVNasdaqBurlington, MA

Minerva Neurosciences

Minerva Neurosciences develops small-molecule product candidates for CNS diseases.

SEC EDGAR ClinicalTrials.gov ir.minervaneurosciences.com

SCHEDULE 13G/AAug 14Latest SEC filing

Aug 12Latest story

August 2026

Minerva Neurosciences names Anthony Aliquo chief accounting officer

Aug 12PeopleMinerva Neurosciences

Minerva reports Q2 2026 results, confirms C19 trial timeline for roluperidone

Aug 7Quarterly updateMinerva Neurosciences roluperidone